Results 101 to 110 of about 3,904 (178)

Evaluation of a pharmacist directed treat to target approach in patients with inflammatory bowel disease receiving upadacitinib or risankizumab. [PDF]

Crohns Colitis 360
Han J, Puangampai A, Man B, Kandah HM, Rubin DT, Choi DK.   +5 more
europepmc   +1 more source

Cost-Effectiveness Analysis of Bimekizumab against Interleukin-23 Inhibitors in Patients with Plaque Psoriasis in Japan. [PDF]

Dermatol Ther (Heidelb)
Igarashi A, Shiraishi K, Saito S, Kudo T, Iizuka Y, Yamamura E, Hase M.   +6 more
europepmc   +1 more source

Safety of Risankizumab during Pregnancy in IBD. [PDF]

Inflamm Bowel Dis
Tsur N, Ben Ya'acov A, Ungar B, Ron Y, Avni-Biron I, Reiss Mintz H, Koslowsky B, Mishael T, Bar Gil Shitrit A.   +8 more
europepmc   +1 more source

Comparative Effectiveness of Four Biologics for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis. [PDF]

Cureus
Abdullah A, Polus L.
europepmc   +1 more source

Efficacy of Risankizumab in Moderate to Severe Psoriasis Considering Body Mass Index: A Scoping Review. [PDF]

Cureus
Sarmiento K, Siqueiros M, Hernández M, Morales G, Orozco V, Pumarejo LF, Gonzalez AD.   +6 more
europepmc   +1 more source

Interleukin-23 Inhibitors in Inflammatory Bowel Disease. [PDF]

BioDrugs
Puca P, Parello S, Colantuono S, Tursi A, Coppola G, Lopetuso LR, Scaldaferri F, Gasbarrini A, Papa A.   +8 more
europepmc   +1 more source

Risankizumab (Skyrizi) [PDF]

Dermatologie pro praxi, 2020
openaire   +1 more source

Esophageal Crohn's Disease Successfully Treated With Risankizumab. [PDF]

ACG Case Rep J
Hallcox T, Stein D.
europepmc   +1 more source

Systemic Immune-Inflammation Index and Systemic Inflammation Response Index in Psoriasis: Limited Utility for Monitoring Response to IL-23 Inhibitors. [PDF]

Dermatol Pract Concept
Bardazzi F, Natale A, Maltoni L, Clarizio G, Brunetti T, Cafasso G, Sacchelli L, Loi C, Piraccini BM, Cedirian S.   +9 more
europepmc   +1 more source

Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. [PDF]

Dermatol Ther (Heidelb)
Magnolo N, Soung J, Frew J, Costanzo A, Ruiz-Santiago H, Eyerich K, Llamas-Velasco M, Bukhalo M, Sivamani RK, Moore A, Wu T, Xie J, Patel M, Ashley D, Kaplan B, Stakias V, Espaillat R, Warren RB.   +17 more
europepmc   +1 more source